Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S

Cancer Research

Volumn 57, Issue 2, 1997, Pages 279-283

  MacDonald, John R ^a   Muscoplat, Charles C ^a   Dexter, Daniel L ^b   Mangold, Gina L ^b   Chen, Shih Fong ^b   Kelner, Michael J ^c   McMorris, Trevor C ^d   Von Hoff, Daniel D ^b  

^a GUILFORD PHARMACEUTICALS INC   (United States)

^b CTRC Institute for Drug Development   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; ILLUDIN S; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG ISOLATION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; MELANOMA CELL; MOUSE; MUSHROOM; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HT29 CELLS; HUMANS; LEUKEMIA P388; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; SESQUITERPENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031031009     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kelner, M. J., McMorris, T. C., Beck, W. T., Zumora, J. M., and Taetle, R. Preclinical evaluation of illudins as anticancer agents. Cancer Res., 47: 3186-3189, 1987.
2. Kelner, M. J., McMorris, T. C., and Taetle, R. Preclinical evaluation of illudins as anticancer agents: basis for selective toxicity. J. Natl. Cancer Inst., 82: 1562-1565, 1990.
3. Kelner, M. J., McMorris, T. C., Estes, L., Rutherford, M., Montoya, M., Goldstein, J., Samson, K., Starr, R., and Taetle, R. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells: unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem. Pharmacol., 48: 403-409, 1994.
4. Kelner, M. J., McMorris, T. C., Estes, L., Starr, R. J., Rutherford, M., Montoya, M., Samson, K. M., and Taetle, R. Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 helicase-deficient cells. Cancer Res., 55: 4936-4940, 1995.
5. Kelner, M. J., McMorris, T. C., and Taetle, R. In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res., 15: 873-878, 1995.
6. McMorris, T. C., Kelner, M. J., Wang, W., Yu, J., Estes, L. A., and Taetle, R. Hydroxymethylacylfulvene (HMAF), an illudin derivative with superior antitumor properties. J. Nat. Prod. (LLoydia), 59: 896-899, 1996.
7. Kelner, M. J., McMorris, T. C., Estes, L., Wang, W., Samson, K. M., and Taetle, R. Efficacy of HMAF illudin analog against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents. Invest. New Drugs, 14: 161-167, 1996.
8. Varki, N. M., Roome, L., Sparkes, R. S., and Miller, J. E. Microscopic metastasis of a human lung carcinoma cell line in athymic nude mice. Int. J. Cancer, 40: 46-52, 1987.
9. Kelner, M. J., McMorris, T. C., Estes, L., Starr, R., Samson, K., Varki, N., and Taetle, R. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res., 15: 867-872, 1995.
10. Goldin, A., Venditti, J. M., MacDonald, J. S., Muggia, F. M., Henney, J. E., and Devita, V. T. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer, 17: 129-142, 1981.
11. Staquet, M. J., Byar, D. P., Sylvan, S. B., and Rozencweig, M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat. Rep., 67: 753-765, 1983.
12. Venditti, J. M., Wesley, R. A., and Plowman, J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv. Pharmacol. Chemother., 20: 1-20, 1984.
13. LoRusso, P. M., Demchik, L., Dan, M., Polin, L., Knight, J., Jones, J., Sun, J-H., McRipley, R. J., Gross, J. L., and Corbett, T. H. Antitumor activity of DMP 840. Proc. Am. Assoc. Cancer Res., 34: 380, 1993.
14. Bousquet, P. F., Brana, M. F., Conlon, D., Fitzgerald, K. M., Perron, D., Cocchiaro, C., Miller, R., Moran, M., George, J., Qian, X-D., Keilhauer, G., and Romerdahl, C. A. Preclinical evaluation of LU 79553: a novel bis-napthalimide with potent antitumor activity. Cancer Res., 55: 1176-1180, 1995.
15. McRipley, R. J., Burns-Horwitz, P. E., Czerniak, P. M., Diamond, R. J., Miller, L. D., Page, R. J., Dexter, D. L., Chen, S-F., Behrens, C. H., Seitz, S. P., and Gross., J. L. Efficacy of DMP-840: a novel bis-napthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res., 54: 159-164, 1994.
16. McMorris, T. C., Kelner, M. J., Wang, W., Moon, S., and Taetle, R. On the mechanism of toxicity of illudins: the role of glutathione. Chem. Res. Toxicol., 3: 574-579, 1990.